Zydus Lifesciences Limited

CLOSEOUT LETTER Zydus Lifesciences Limited MARCS-CMS 584856 — November 03, 2022 More Warning Letters Warning Letters About Warning and Close-Out Letters Reference #: 3002984011 Product: Drugs Recipient: Recipient Name Dr. Shavril Patel Recipient Title Managing Director Zydus Lifesciences Limited Cadila Healthcare Limited Khoraj (Gandhinagar) Nr. Vaishmodevi Circle Ahmedabad 382481 Gujarat India Issuing Office: Center for Drug Evaluation and Research | CDER United States Dear Dr. Patel: The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 320-20-05 dated October 29, 2019. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ for Rebecca Parrilla Compliance Officer Division of Drug Quality I Content current as of: 11/28/2022 Regulated Product(s) Drugs